A syngeneic model of colon cancer sensitive to immune checkpoint blockade

    • Model features: CD8+ T cell-mediated control of tumor growth, MDSCs tumor infiltration
    • Tumor cell line: MC38 tumor cells
    • Tumor implantation: subcutaneous
    • Standards: immune checkpoint inhibitors (anti-PD1, PDL1, CTLA4)
    • Readouts: body weight, tumor size, survival
MC38 syngeneic tumor model CRO cancer immunotherapy

Subcutaneous MC38 colon tumor model is sensitive to PD1/PDL1 axis blockade.
Mice were challenged with MC38 cells and treated with either isotype, anti-PD1 or anti-PDL1 antibodies. Tumor growth and survival were monitored overtime.

In vivo efficacy & mechanism of action studies for novel immunotherapies

in vivo efficacy study CRO breast cancer

Straightforward in vivo efficacy studies

  • N=10: Standard groups of 10 mice including groups exposed to test compound alone and in combination with reference therapy.
  • Weekly reports: monitoring tumor growth, body weight, and survival
in vivo cancer immunotherapy studies CRO services

Flexible sampling options

  • Monitoring response over time: satellite mice, serial bleeding, intra-tumoral biopsies
  • On-demand sample collection: blood, serum, plasma, tumor, organ samples
in vivo mechanism actin immunotherapy breast cancer

A flexible platform to quantify tumor-microenvironment & peripheral markers

  • Multiplex immunophenotyping by flow cytometry & digital pathology
  • Spatial transcriptomics & proteomics
  • Tumor microdialysis

Sensitivity of the syngeneic MC38 colon cancer model to Immune checkpoint blockers

Exposure to antibiotics limits response to Immune checkpoint inhibitors

The anti-tumor activity of anti-PD1 is partially abrogated by animal exposure to antibiotics.

Mice were exposed to antibiotics (ABX) and then subcutaneously inoculated with MC38 tumor cells. Treatment with Vehicle and anti-PD1 was initiated on Day 6 and repeated three times. Tumor growth and survival were monitored over time. Individual tumor growth (A), mean tumor volume (B), and survival (C) are presented.

anti tumor activity anti-PD1 in vivo model MC38 CRO services

Evated level of Circulating Arginine is associated with sensitivity to Immune Checkpoint Blockers

In 2022, a study conducted by Explicyte, in collaboration with teams from Institut Bergonié (Antoine Italiano) and Gustave Roussy, demonstrated that levels of circulating arginine are associated with the response to immune checkpoint blockers. These results were supported by both clinical and preclinical evidence.

High levels of ARG correlate with ICI-induced tumor regression in a mouse MC38 colon cancer syngeneic model.

(A) Individual tumor growth curves of MC38 tumor-bearing mice treated with either anti-PD1 or anti-PDL1, classified according to their baseline ARG levels as High (bold line) and Low (light line). Arginine levels were measured by ELISA. (B) Kaplan-Meier curve of overall survival upon anti-PD1/PDL1 antibody treatment, categorized by baseline ARG levels and treatment. The p-value was calculated using the log-rank test between ICI – ARG High and Low groups.

annals of oncology

Why working with Explicyte?

in Immuno-Oncology

  • 150+ in vivo campaigns conducted over the past 10 years
  • 20+ peer-reviewed publications in key immuno-oncology journals
  • Bespoke study designs based on client objectives and literature


  • A dedicated study director (PhD level) from experimental plan to final report
  • Weekly reports to provide regular updates & adapt experimental strategy
  • Comprehensive analytical platform to decipher anti-tumor response

Your contacts

explicyte team 2024

Talk to our team !

Paul Marteau, PharmD (preclinical study director), Imane Nafia, PhD (CSO), Loïc Cerf, MSc (COO), Alban Bessede, PhD (founder, CEO), Jean-Philippe Guégan, PhD (translational study director)

Tell us about your project !

    Select department:

    WordPress Lightbox